BioCryst Pharmaceuticals, Inc. Net Debt/EBITDA

Net Debt/EBITDA of BCRX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt/EBITDA growth rates and interactive chart.


Highlights and Quick Summary

  • Net Debt/EBITDA for the quarter ending September 30, 2022 was -16.5 (a 169.12% increase compared to previous quarter)
  • Year-over-year quarterly Net Debt/EBITDA increased by 943.66%
  • Annual Net Debt/EBITDA for 2021 was -0.47 (a -440.48% decrease from previous year)
  • Annual Net Debt/EBITDA for 2020 was 0.14 (a -83.96% decrease from previous year)
  • Annual Net Debt/EBITDA for 2019 was 0.85 (a -4.3% decrease from previous year)
Visit stockrow.com/BCRX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt/EBITDA of BioCryst Pharmaceuticals, Inc.

Most recent Net Debt/EBITDAof BCRX including historical data for past 10 years.

Interactive Chart of Net Debt/EBITDA of BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -16.5 -6.13 -3.35
2021 -1.58 -2.41 -2.59 -0.88 -0.47
2020 0.43 2.26 3.62 1.49 0.14
2019 112.99 0.58 1.37 1.95 0.85
2018 2.95 3.18 3.69 3.29 0.89
2017 5.26 10.75 4.01 7.39 1.62
2016 3.95 3.31 3.17 1.89 0.05
2015 3.0 5.61 -16.64 4.92 1.33
2014 4.91 11.11 11.54 0.21 1.62
2013 1.33 1.89 0.11 -0.22 0.27
2012 0.57 1.46 0.72 3.01 0.18

Business Profile of BioCryst Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology